6533b7dafe1ef96bd126ee47
RESEARCH PRODUCT
COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?
Oronzo BrunettiAfshin DerakhshaniBehzad BaradaranAntonio GalvanoAntonio RussoNicola SilvestrisNicola Silvestrissubject
OncologyOpinionmedicine.medical_specialty2019-20 coronavirus outbreakCancer ResearchtherapyCoronavirus disease 2019 (COVID-19)business.industrySettore MED/06 - Oncologia MedicaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)screeningCancerCOVID-19medicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282OncologyCOVID-19 cancer prognosis screening therapyInternal medicinemedicinecancerprognosisbusinessdescription
The world is facing a new pandemic caused by a novel beta coronavirus (COVID 19), which causes severe respiratory coronavirus syndrome (SARS-CoV-2). Unfortunately, there are currently no US Food and Drug Administration (FDA) approved medications for the treatment of COVID-19 patients. High mortality rates in frail patients is a notable feature of the virus registered since the onset of COVID-19 pandemic. Above all, elderly patients or those with underlying chronic illnesses and compromised immune system are most at risk (1). Thus, the consideration is that the possible coexistence, in the same individual, of a cancer diagnosis and a COVID-19 infection could generate a synergistic negative prognostic effect.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-04-01 | Frontiers in Oncology |